MedPath

Eleclazine

Generic Name
Eleclazine
Drug Type
Small Molecule
Chemical Formula
C21H16F3N3O3
CAS Number
1443211-72-0
Unique Ingredient Identifier
PUY08529FK

Overview

Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic Heart Disease, Ventricular Arrhythmia, and Long QT Syndrome Type 3, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2015/05/12
Phase 1
Completed
2015/04/08
Phase 1
Completed
2015/03/03
Phase 2
Withdrawn
2015/02/19
Phase 1
Completed
2015/02/19
Phase 1
Completed
2014/11/25
Phase 3
Terminated
2014/11/14
Phase 2
Terminated
2014/04/04
Phase 2
Completed
2013/05/08
Phase 1
Completed
2013/05/06
Phase 1
Completed

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.